Kyung NAM Pharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Kyung NAM Pharm makes everyday consumer health products, most notably Lemona, a powdered vitamin supplement, alongside over-the-counter medicines, a placenta-based health drink, a throat-infection treatment, and an antifungal remedy.
Its products reach consumers through tens of thousands of pharmacies nationwide, as well as convenience stores, large supermarkets, and health-and-beauty retailers. Listed on KOSDAQ, Korea's small-cap board, the company earns the largest share of its revenue from its over-the-counter medicines segment, with general food and health-functional food lines making up most of the remainder.
Summary is AI-generated and may contain errors · figures from DART filings
Kyung NAM Pharm in five facts
What does Kyung NAM Pharm do?
Kyung NAM Pharm makes everyday consumer health products, most notably Lemona, a powdered vitamin supplement, alongside over-the-counter medicines, a placenta-based health drink, a throat-infection treatment, and an antifungal remedy.
Where is Kyung NAM Pharm listed and in which sector?
Kyung NAM Pharm (Korean name: 경남제약) trades under KRX code 053950 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Kyung NAM Pharm?
Its market capitalisation was US$27.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Kyung NAM Pharm's latest annual revenue and operating profit?
For fiscal year 2025, Kyung NAM Pharm reported revenue of US$42.2M, an operating loss of US$1.3M and a net loss of US$6.8M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 8.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- DisclosureCapital raise · Oct 12
- DisclosureOct 12
- [Amended] Material event report (rights offering)Capital raise · Oct 12 · 5 versions
- [Amended] Shareholder register closure / record date setSep 18
- DisclosureSep 16
- [Amended] Shareholder register closure / record date setSep 7
- [Amended] Securities registration statement (equity)Sep 7
- [Amended] Decision to acquire shares/equity in another company
Kyung NAM Pharm updated the disclosed terms of an acquisition of Ascendio, now worth US$9.24M.
M&A · Aug 10 - [Amended] Material event report (rights offering)
Kyung NAM Pharm updated the terms of a private placement (third-party allotment) to raise US$4.32M, about 16.3% of its market value.
Capital raise · Jul 10 · 2 versions - Decision to acquire shares/equity in another company
Kyung NAM Pharm disclosed an acquisition of Ascendio, worth US$8.62M.
M&A · Jul 7 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Jun 22
- Trading suspension (share consolidation/split registration)M&A · Apr 9
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Kyung NAM Pharm reported separate results for FY2025: revenue of US$38.6M (−8% year on year), an operating loss of US$1.14M and a net loss of US$5.88M (from a profit a year earlier).
Earnings · Feb 20